Truist Financial Upgrades Corcept Therapeutics (NASDAQ:CORT) to Strong-Buy

Corcept Therapeutics (NASDAQ:CORT) was upgraded by research analysts at Truist Financial to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

CORT has been the topic of a number of other research reports. Canaccord Genuity Group lifted their price objective on Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. HC Wainwright cut their target price on shares of Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research report on Wednesday, December 31st. Finally, UBS Group started coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $77.67.

Corcept Therapeutics Stock Down 4.8%

Shares of CORT stock opened at $38.53 on Wednesday. The company’s fifty day simple moving average is $37.47 and its two-hundred day simple moving average is $61.00. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $117.33. The stock has a market cap of $4.10 billion, a P/E ratio of 46.99 and a beta of 0.29. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The firm had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.26 EPS. Analysts predict that Corcept Therapeutics will post 1.36 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director G Leonard Baker, Jr. bought 100,000 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was purchased at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. This trade represents a 9.55% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William Guyer sold 11,767 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $36.01, for a total value of $423,729.67. Following the transaction, the insider directly owned 2,231 shares in the company, valued at approximately $80,338.31. This represents a 84.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 60,000 shares of company stock worth $2,241,035. Company insiders own 20.80% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Institutional investors have recently bought and sold shares of the stock. Torren Management LLC bought a new position in Corcept Therapeutics during the fourth quarter valued at $25,000. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter worth about $25,000. Clearstead Advisors LLC lifted its holdings in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares during the last quarter. Atlas Capital Advisors Inc. purchased a new position in shares of Corcept Therapeutics during the 4th quarter worth about $31,000. Finally, Hantz Financial Services Inc. boosted its stake in shares of Corcept Therapeutics by 113.7% during the 4th quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 524 shares during the period. 93.61% of the stock is currently owned by institutional investors.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel — the regulatory win is the primary commercial catalyst and triggered the recent multi‑day rally due to survival benefit data and earlier‑than‑expected decision. FDA Approves (BusinessWire)
• Positive Sentiment: Analyst/firm support: multiple firms raised or reiterated positive views (Truist to “strong‑buy”, Canaccord price target increase reported, HC Wainwright kept a Buy rating), which supports upside potential as the market prices in Lifyorli’s commercial opportunity. Analyst Coverage (Benzinga)
• Positive Sentiment: Insider confidence signal: market commentary highlighted a mid‑March purchase by a director (~100,000 shares) that likely helped amplify bullish positioning ahead of the approval. Insider Buy Analysis (QuiverQuant)
• Neutral Sentiment: Market structure/volatility: trading was temporarily halted (LULD pause) and the name has posted very large intraday moves as investors re‑price the company; expect elevated volume and short‑term volatility. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple securities‑class‑action firms have filed/issued alerts alleging misstatements tied to prior FDA issues and patent litigation — several firms are seeking lead plaintiffs and note an April 21, 2026 deadline; these suits create tangible legal and financial overhang. Hagens Berman Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: Corcept disclosed a sale by William Guyer (11,767 shares on Mar 20), which may be viewed negatively by some investors despite offsetting director purchases. Insider Sale SEC Filing

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.